Last €6.41 EUR
Change Today -0.101 / -1.55%
Volume 0.0
As of 3:16 PM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

thrombogenics nv (TG4) Snapshot

Open
€6.39
Previous Close
€6.51
Day High
€6.48
Day Low
€6.35
52 Week High
04/25/14 - €24.18
52 Week Low
12/17/14 - €6.01
Market Cap
231.3M
Average Volume 10 Days
512.2
EPS TTM
--
Shares Outstanding
36.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THROMBOGENICS NV (TG4)

Related News

No related news articles were found.

thrombogenics nv (TG4) Related Businessweek News

No Related Businessweek News Found

thrombogenics nv (TG4) Details

ThromboGenics NV, an integrated biopharmaceutical company, is engaged in developing and commercializing ophthalmic and oncology medicines in Belgium and interntionally. The company offers JETREA for the treatment of symptomatic vitreomacular traction. It has a collaboration agreement with BioInvent International AB to develop anti-factor VIII, an anti-coagulation treatment for various indications, such as the prevention and treatment of deep vein thrombosis, and the treatment of atrial fibrillation; and anti-placental growth factor, an anti-angiogenic component for the treatment of various disorders, including cancer, age-related macula degeneration, retinopathy, and inflammation. The company also has a research and license agreement with Bharat Biotech; a production agreement with Fujifilm Diosynth Biotechnologies UK Limited; a license agreement Grifols and NuVue Technologies, Inc.; a life sciences research partnership with VZW; agreements with Eleven Biotherapeutics, Bicycle Therapeutics, and Flanders Institute for Biotechnology; and cooperation agreements with Centrum voor Moleculaire en Vasculaire Biologie and KULeuven. ThromboGenics NV was founded in 1991 and is headquartered in Leuven, Belgium.

154 Employees
Last Reported Date: 04/9/14
Founded in 1991

thrombogenics nv (TG4) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: €448.0K
Compensation as of Fiscal Year 2013.

thrombogenics nv (TG4) Key Developments

ThromboGenics NV Presents at HSBC Healthcare Day 2014, Nov-12-2014

ThromboGenics NV Presents at HSBC Healthcare Day 2014, Nov-12-2014 . Venue: Hilton, Frankfurt, Germany.

ThromboGenics' JETREA(R) Gains Approval in South Korea

ThromboGenics NV announced that JETREA(R) (ocriplasmin) has been approved in South Korea for the treatment of adults with symptomatic vitreomacular adhesion (VMA) including when associated with macular hole of diameter less than or equal to 400 microns. South Korea is the fourth country in Asia to grant JETREA(R) approval. The product has already gained approval in Malaysia, Singapore and Taiwan. ThromboGenics' partner Alcon, which is commercializing JETREA(R) outside the US, will be responsible for the launch of the drug in South Korea.

ThromboGenics NV Reports Unaudited Consolidated Earnings Results for the First Half Ended June 30, 2014

ThromboGenics NV reported unaudited consolidated earnings results for the first half ended June 30, 2014. For the period, the company reported income of EUR 7,149,000 compared to EUR 102,725,000 a year ago. Operating result negative was EUR 24,414,000 compared to operating result of EUR 54,076,000 a year ago. Loss before income tax was EUR 23,803,000 compared to result before income tax of EUR 54,609,000 a year ago. Net loss for the period attributable to equity holders of the company was EUR 23,849,000 or EUR 0.66 per diluted share, compared to net result for the period of EUR 54,608,000 or EUR 1.48 per diluted share a year ago. Net cash used from operating activities was EUR 8,987,000 compared to net cash from operating activities of EUR 46,409,000 a year ago. Acquisition of intangible assets was EUR 13,000 compared to EUR 3,322,000 a year ago. Acquisition of property, plant and equipment was EUR 471,000 compared to EUR 1,535,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TG4:GR €6.41 EUR -0.101

TG4 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TG4.
View Industry Companies
 

Industry Analysis

TG4

Industry Average

Valuation TG4 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.3x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THROMBOGENICS NV, please visit www.thrombogenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.